Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Total Valuation
Lisata Therapeutics has a market cap or net worth of $22.42M. The enterprise value is $2.77M.
Market Cap$22.42M
Enterprise Value$2.77M
Share Statistics
Lisata Therapeutics has 8,755,948 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,755,948
Owned by Insiders8.06%
Owned by Institutions2.66%
Financial Efficiency
Lisata Therapeutics’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is -72.64%.
Return on Equity (ROE)-0.68
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-72.64%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee38.46K
Profits Per Employee-768.65K
Employee Count26
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lisata Therapeutics is ―. Lisata Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.84
Price to FCF―
Price to Operating Cash Flow-1.40
PEG Ratio―
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 1.00M and earned -19.98M in profits. Earnings per share was -2.40.
Revenue1.00M
Gross Profit1.00M
Operating Income-22.41M
Pretax Income-20.78M
Net Income-19.98M
EBITDA-22.23M
Earnings Per Share (EPS)-2.40
Cash Flow
In the last 12 months, operating cash flow was -16.40M and capital expenditures -56.00K, giving a free cash flow of -16.40M billion.
Operating Cash Flow-16.40M
Free Cash Flow-16.40M
Free Cash Flow per Share-1.87
Dividends & Yields
Lisata Therapeutics pays an annual dividend of $0.31, resulting in a dividend yield of ―
Dividend Per Share$0.31
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change-14.53%
50-Day Moving Average2.63
200-Day Moving Average2.63
Relative Strength Index (RSI)45.71
Average Volume (3m)52.29K
Important Dates
Lisata Therapeutics upcoming earnings date is Nov 6, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend DateOct 28, 2013
Financial Position
Lisata Therapeutics as a current ratio of 6.16, with Debt / Equity ratio of 0.22%
Current Ratio6.16
Quick Ratio6.16
Debt to Market Cap<0.01
Net Debt to EBITDA0.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lisata Therapeutics has paid -798.00K in taxes.
Income Tax-798.00K
Effective Tax Rate0.04
Enterprise Valuation
Lisata Therapeutics EV to EBITDA ratio is -0.39, with an EV/FCF ratio of -0.45.
EV to Sales8.75
EV to EBITDA-0.39
EV to Free Cash Flow-0.45
EV to Operating Cash Flow-0.45
Balance Sheet
Lisata Therapeutics has $21.97M in cash and marketable securities with $47.00K in debt, giving a net cash position of -$21.92M billion.
Cash & Marketable Securities$21.97M
Total Debt$47.00K
Net Cash-$21.92M
Net Cash Per Share-$2.50
Tangible Book Value Per Share$3.50
Margins
Gross margin is 88.04%, with operating margin of -2240.90%, and net profit margin of -1998.50%.
Gross Margin88.04%
Operating Margin-2240.90%
Pretax Margin-2078.30%
Net Profit Margin-1998.50%
EBITDA Margin-2223.50%
EBIT Margin-2240.90%
Analyst Forecast
The average price target for Lisata Therapeutics is $23.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$23.50
Price Target Upside828.85% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast12.95%